Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Chugai And Taisho Pharmaceutical To Jointly Develop And Market Osteoporosis Drug

This article was originally published in PharmAsia News

Executive Summary

Chugai Pharmaceutical and Taisho Pharmaceutical signed an agreement May 14 to jointly develop and market activated vitamin D derivative ED-71 to treat osteoporosis. Originally developed by Chugai, ED-71 has higher bone strengthening effects compared to current activated vitamin D drugs, according to the companies. ED-71 is now in Phase III trials in Japan. (Click here for more - Japanese language)

Table

View full table

Tags:
Latest Headlines

Stock Watch: Novartis And The Changing Face Of Big Pharma

Cash-Rich SynOx Well Placed To Compete In Hot TGCT Field

Quick Listen: Scrip's Five Must-Know Things

Avistone Wins China Approval For First C-Met Inhibitor In Glioblastoma

See All
UsernamePublicRestriction

Register

SC068482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By